Ad-p53 gene therapy / MultiVir - LARVOL DELTA

Tumor suppressor immune gene therapy to reverse immunotherapy resistance. (PubMed, Cancer Gene Ther) - "These results imply the ability of Ad-p53 to induce efficacious local and systemic antitumor immune responses with the potential to reverse resistance to immune checkpoint inhibitor therapy when combined with CD122/132 agonists and immune checkpoint blockade. Our findings further imply that Ad-p53 has multiple complementary immune mechanisms of action, which support future clinical evaluation of triplet Ad-p53, CD122/132 agonist, and immune checkpoint inhibitor combination treatment."

IO biomarker • Journal • Gene Therapies • Immune Modulation • Immunology • Inflammation • Oncology • CD8 • CTNNB1 • IL10 • IL15 • IL2 • TGFB1

Analysis of Adenoviral p53 Gene Therapy Clinical Trials in Recurrent Head and Neck Squamous Cell Carcinoma. (PubMed, Front Oncol) - "Future Ad-p53 clinical trials should have favorable p53 biomarker profiles inclusion criteria and Ad-p53 dosing above 7 × 10 viral particles/cm of injected tumor volume. Preliminary gene expression profiling identified p53 mechanisms of action associated with responses to immune checkpoint blockade supporting evaluation of Ad-p53 in combination with immune checkpoint inhibitors."

Clinical • IO biomarker • Journal • Gene Therapies • Head and Neck Cancer • Immune Modulation • Inflammation • Oncology • Solid Tumor • Squamous Cell Carcinoma • Squamous Cell Carcinoma of Head and Neck • CD8 • TGFB1 • TP53